PharmaEngine of Taiwan acquired Asia-Pacific rights (including China) to a radiology-enhancing nanomedicine product from Nanobiotix S.A., a French company. NBTXR3 is currently undergoing a Phase I study trial in Europe as a treatment for soft tissue sarcoma. According to Nanobiotix, NBTXR3 increases the effect of radiation by a factor of three in mouse models without affecting nearby tissue. More details.... Stock Symbol: (TWO: 4162) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});